Your HDL is 26 mg/dL: low, but expected on blast. Your LDL is 145 mg/dL: elevated, also expected. But your triglycerides are 250 mg/dL, and that is a different category of problem. Unlike HDL suppression and LDL elevation, high triglycerides on cycle tell a story about metabolic stress that goes beyond "standard AAS dyslipidemia" and points to a more urgent set of interventions.
The clinical picture here matters. A TG of 250 with HDL of 26 puts your TG/HDL ratio at 9.6, which is far beyond the 3.5 threshold for small dense LDL. That means your LDL of 145 is likely composed of the more atherogenic particles, not the fluffy ones. This is why you cannot just look at LDL in isolation. On cycle, a high TG number often signals that your liver is under metabolic stress from insulin resistance, not just from androgens. If you are also carrying extra body fat, especially visceral fat, the effect compounds. A common mistake is assuming that because your LDL is only mildly elevated, the risk is low. The TG/HDL ratio tells a different story, and it is the number that should drive your intervention strategy.
Triglycerides vs. Cholesterol: Different Problems
Most AAS users think of "lipids" as a single category, but triglycerides and cholesterol are metabolically distinct. Cholesterol is structural: it builds cell membranes and hormones. Triglycerides are energy storage: they are what your liver packages into VLDL particles and sends to your tissues for storage or fuel.
This distinction matters because the drivers are different. High LDL on AAS is primarily driven by androgen receptor-mediated changes in hepatic LDL receptor expression. High triglycerides are driven by increased VLDL production in the liver: which is fueled by carbohydrate intake, oral AAS hepatotoxicity, and insulin resistance. A user with high LDL and normal triglycerides has a different problem than a user with both high LDL and high triglycerides.
The mechanism is worth understanding because it changes what you do. VLDL particles are assembled in the liver from triglycerides and apolipoprotein B100. When you eat more carbohydrates than your liver can oxidize or store as glycogen, the excess is converted to fatty acids via de novo lipogenesis. Those fatty acids get packaged into VLDL and shipped out. Insulin normally suppresses this process, but when insulin resistance develops, the suppression weakens and VLDL output rises. On AAS, oral compounds and GH both worsen insulin sensitivity, which is why they hit triglycerides so hard. High-dose testosterone also raises hepatic lipase, which remodels VLDL and LDL into smaller particles. This is why the TG/HDL ratio is so tightly linked to cardiovascular risk in this population. It captures the metabolic derangement that LDL alone misses.
Triglycerides
What Makes Triglycerides Rise on AAS
Four factors consistently drive triglyceride elevation in AAS users, and identifying which one applies to you determines the most effective intervention.
Oral AAS. 17-alpha-alkylated orals are the single strongest driver. The first-pass hepatic effect increases VLDL production directly. Anavar, Winstrol, and Anadrol users consistently show the highest triglyceride values. The effect is dose-dependent and rapid: triglycerides rise within days of starting an oral.
The dose response with orals is steep. In clinical studies, 20 mg/day of stanozolol raises triglycerides by roughly 40-60% within four weeks. Anavar at 40 mg/day can push a clean eater from 120 to 220 mg/dL. Anadrol is even more aggressive, often doubling triglycerides within two weeks. The effect is not linear; it accelerates as dose increases. For example, going from 50 mg to 100 mg of Winstrol can add 80-100 mg/dL on top of an already elevated baseline. If you are running multiple orals, the increase is additive, not just cumulative. A practical rule: if your triglycerides are above 200 and you are on any oral, the oral is the primary suspect. Switching to the injectable form of the same compound, or dropping it entirely, is the first move. Do not try to out-supplement a 500 mg/week oral stack with fish oil alone.
Growth hormone. GH induces insulin resistance in a dose-dependent manner, and insulin resistance is a direct driver of VLDL overproduction. Users on 4+ IU of GH per day commonly see triglycerides rise by 30-60 mg/dL. This effect is independent of the AAS component and additive when both are used together.
High-dose testosterone. Testosterone above 500 mg per week increases hepatic lipase activity and VLDL production. The effect is modest compared to orals but becomes significant at higher doses and when combined with other triglyceride-raising factors.
High-dose testosterone alone is a weaker driver, but it becomes relevant in specific scenarios. At 600 mg/week, expect a 10-20 mg/dL rise in triglycerides in most users. At 1 gram or more, the increase can reach 40-50 mg/dL, especially if you are already insulin resistant. The effect is mediated by increased hepatic lipase activity, which accelerates VLDL clearance but also produces smaller, denser LDL particles. This is why you can see a normal TG level but still have an elevated atherogenic particle count. A common edge case is the bodybuilder who runs 500 mg test with 300 mg deca and keeps triglycerides at 180, then adds 20 mg of Anavar and jumps to 260. The testosterone was not the problem, but it set the stage. If you are on high-dose test and your TG is creeping up, check your fasting insulin and HbA1c. The insulin resistance is often the deeper issue.
High-carbohydrate diet. A diet high in refined carbohydrates amplifies VLDL production in the liver. For users already on orals, a high-carb diet can push triglycerides 50-100 mg/dL higher than a lower-carb approach with the same compound regimen. This is the most modifiable factor and the one most often overlooked.
The TG/HDL Ratio: Predicting Small Dense LDL
The ratio of triglycerides to HDL is one of the most powerful predictors of atherogenic dyslipidemia — specifically the presence of small, dense LDL particles. When the ratio exceeds 3.5 (in mg/dL units), it indicates that your LDL particles are predominantly the small, dense type that is most damaging to arterial health. This is because high triglycerides drive the production of VLDL, which is then remodeled into small, dense LDL through the action of cholesteryl ester transfer protein (CETP).
The TG/HDL ratio is not just a proxy for LDL particle size. It also correlates with remnant cholesterol, which is the cholesterol carried by VLDL and IDL particles. These remnants are highly atherogenic because they penetrate the arterial wall easily and are taken up by macrophages without receptor-mediated clearance. A ratio above 3.5 indicates you have a significant remnant burden, even if your LDL cholesterol looks acceptable. For example, a man with LDL of 100, HDL of 35, and TG of 180 has a ratio of 5.1, placing him at higher risk than someone with LDL of 140, HDL of 50, and TG of 100 (ratio 2.0). When you are on cycle, your liver is producing more VLDL, and the remnants are the byproduct. This is why some clinicians argue that non-HDL cholesterol (total minus HDL) is a better target than LDL alone. Your non-HDL is 145 plus 26 minus 26? No, non-HDL is total cholesterol minus HDL. If your total is 220 and HDL is 26, non-HDL is 194, which is high. The TG/HDL ratio ties it all together.
A practical example: triglycerides of 200 divided by HDL of 40 gives a ratio of 5.0: well above the 3.5 threshold, indicating a high-risk particle distribution. The same triglycerides of 200 with an HDL of 70 gives a ratio of 2.9: below threshold, suggesting larger, less dangerous LDL particles. This is why the TG/HDL ratio provides information that neither marker alone can give, and why tracking both together is more useful than tracking either in isolation.
TG/HDL Ratio: Quick Interpretation
Managing Triglycerides on Cycle
The most effective intervention for high triglycerides on AAS is removing or reducing the offending compound. Switching from an oral to an injectable equivalent resolves elevated triglycerides in the majority of cases: often within 2-3 weeks. If your triglycerides are elevated and you are using an oral, this should be your first intervention before adding supplements or changing diet.
A common mistake is switching from orals to injectables but keeping the same diet and expecting triglycerides to normalize. The oral removal is necessary, but if you are still eating 400 grams of carbs with a high sugar load, your TG will stay elevated, just less so. Another mistake is relying on omega-3s alone. At 3-4 grams of EPA plus DHA, you might drop from 250 to 200, but that still leaves you above the 150 optimal threshold. The evidence shows that combining compound adjustment, carb reduction, and omega-3s produces the most reliable results. Also, do not forget the timing. Triglyceride levels are extremely sensitive to recent meals. A non-fasting measurement can be 50-100 mg/dL higher than a fasting one. Always test after a 12-hour fast, and avoid alcohol for 48 hours before the draw. If you are on a blast and your TG comes back at 180, that might be acceptable, but if it is 350, you need to act. The intervention is not optional; it is the difference between manageable risk and pancreatitis territory.
Diet also matters. Reducing refined carbohydrates and added sugars consistently lowers triglycerides by 30-50% in compliant individuals, regardless of AAS use. This effect is independent of and additive to compound adjustment. A lower-carb approach (under 200 g/day from non-fiber sources) is the most effective dietary strategy for triglyceride reduction on cycle.
Omega-3 fatty acids at 3-4 grams of EPA plus DHA per day reduce triglycerides by 20-30% on average — the most evidence-supported supplement for this specific indication. The effect is dose-dependent, with higher doses producing greater reductions. Fish oil, krill oil, and algal oil are all effective; the key is the total EPA plus DHA content, not the source.